<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716388</url>
  </required_header>
  <id_info>
    <org_study_id>2018-362</org_study_id>
    <nct_id>NCT03716388</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC</brief_title>
  <official_title>Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC : a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dayanand Medical College and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Colitis &amp; Crohn's Foundation (India)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dayanand Medical College and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcerative colitis is a chronic idiopathic inflammatory disease of the colon that is&#xD;
      characterized by abdominal pain and bloody diarrhea. The pathogenesis of UC involves a&#xD;
      complex interplay of genetic factors, immune dysregulation and environmental triggers.&#xD;
      Conventional therapies for UC (including 5-aminosalicylates, corticosteroids, azathioprine or&#xD;
      6-mercaptopurine and biologics) focus on altering the immune response by suppression of&#xD;
      immune cells. However, the primary pathogenic mechanism underlying UC maybe gut microbiota&#xD;
      dysbiosis and a dysfunctional intestinal barrier resulting in an aberrant host immune&#xD;
      response. Several studies have shown reduced microbial diversity in UC patients with under&#xD;
      representation of anti-inflammatory phyla (Bacteroides and Firmicutes), and a relative&#xD;
      increase of pro-inflammatory phyla (Proteobacteria and Actinobacteria). Motivated by this,&#xD;
      therapies targeting intestinal dysbiosis (prebiotics, probiotics, synbiotics and fecal&#xD;
      microbiota transplant (FMT)) have thus been tried in patients with UC. Though several case&#xD;
      series and subsequently four high quality randomized controlled trails have established the&#xD;
      efficacy of FMT in induction of remission in active UC, all these studies have used it as an&#xD;
      add-on therapy, along with the previously ongoing conventional therapies. The investigators&#xD;
      aim to assess the safety and efficacy of FMT as the sole modality for induction of remission&#xD;
      in patients with newly diagnosed active UC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective randomised placebo-controlled trial. Newly diagnosed treatment&#xD;
      naive patients with mild to moderately severe UC will be recruited (n=15). The patients will&#xD;
      be randomized into 3 groups; i.e group I (n=5): FMT with placebo, group II (n=5): FMT with&#xD;
      mesalamine, group III (n=5): Placebo infusion with mesalamine. The patients will undergo&#xD;
      colonoscopic administration of fecal slurry (groups I and II) or placebo (group III) at weeks&#xD;
      0,2,6,10 and 14. Mesalamine will be administered in a dose of 4g/day. In case of clinical&#xD;
      worsening during the study, a short course of steroids will be added. The primary end point&#xD;
      will be clinical remission (Mayo score ≤2, all subscores ≤ 1) at week 14. Secondary end&#xD;
      points will be achievement of endoscopic remission (endoscopic Mayo score 0) and histological&#xD;
      remission (Nancy grade 0, 1) at the end of 14 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>Week 14</time_frame>
    <description>Mayo score ≤2, each subscore ≤1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Weeks 0,2,6,10,14</time_frame>
    <description>Reduction of Mayo score ≥30% and ≥3 points compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>Week 14</time_frame>
    <description>Endoscopic Mayo subscore 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological remission</measure>
    <time_frame>Week 14</time_frame>
    <description>Nancy grade 0 or 1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis Chronic Mild</condition>
  <condition>Ulcerative Colitis Chronic Moderate</condition>
  <arm_group>
    <arm_group_label>FMT Vs Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT Vs Mesalamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Infusion Vs Mesalamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.</description>
    <arm_group_label>FMT Vs Mesalamine</arm_group_label>
    <arm_group_label>FMT Vs Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine Granules</intervention_name>
    <description>Mesalamine granules 4 grams a day</description>
    <arm_group_label>FMT Vs Mesalamine</arm_group_label>
    <arm_group_label>Placebo Infusion Vs Mesalamine</arm_group_label>
    <other_name>Rowasa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Water with food grade colour to resemble fecal slurry</description>
    <arm_group_label>Placebo Infusion Vs Mesalamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo granules</intervention_name>
    <description>Granules resembling mesalamine granules, 4 grams a day</description>
    <arm_group_label>FMT Vs Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active UC:&#xD;
&#xD;
               1. UC diagnosed based on history of chronic (&gt;4 weeks), inflammatory (with blood and&#xD;
                  mucous) diarrhoea&#xD;
&#xD;
               2. Total Mayo Score 4-10, Mayo endoscopic sub-score of &gt;1&#xD;
&#xD;
               3. Histopathology suggestive of UC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe UC (Total Mayo 11-12, Endoscopic Mayo Score 3)&#xD;
&#xD;
          -  Uncertainty about diagnosis of UC : Infective colitis/ Indeterminate Colitis/ Crohn's&#xD;
             Colitis&#xD;
&#xD;
          -  Associated irritable bowel syndrome (IBS)&#xD;
&#xD;
          -  Past history of surgery or colorectal surgery&#xD;
&#xD;
          -  Exposure to antibiotics or probiotics in the last 4 weeks&#xD;
&#xD;
          -  Patients with evidence of infections like C. difficile, cytomegalovirus, HIV,&#xD;
             parasitic infections or extra-intestinal infections requiring antibiotics.&#xD;
&#xD;
          -  Significant cardiopulmonary co-morbidities (high risk for repeated colonoscopy)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Refusal to consent for repeated colonoscopies.&#xD;
&#xD;
        Donor&#xD;
&#xD;
          -  Single donor (voluntary healthy individual) after informed consent&#xD;
&#xD;
          -  Inclusion criteria for donor&#xD;
&#xD;
               -  No personal or family history of UC or any other autoimmune disease or malignancy&#xD;
&#xD;
               -  Screened by stool microscopy and culture for common detectable enteric pathogens&#xD;
                  (Salmonella, Shigella, Campylobacter, Vibrio cholera, E. coli, Clostridium&#xD;
                  difficile, Giardia lamblia and Cryptosporidium) at the start of the study and&#xD;
                  every 4 weeks thereafter.&#xD;
&#xD;
               -  Negative for antibodies against hepatitis A, C and E, hepatitis B surface antigen&#xD;
                  (HBsAg), syphilis and human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Exclusion criteria for donor&#xD;
&#xD;
               -  High-risk sexual behaviors&#xD;
&#xD;
               -  Communicable illnesses&#xD;
&#xD;
               -  Antibiotic treatment within the past 3 months&#xD;
&#xD;
               -  Intrinsic gastrointestinal illnesses such as irritable bowel syndrome,&#xD;
                  inflammatory bowel disease, gastrointestinal malignancies or major&#xD;
                  gastrointestinal surgical procedures&#xD;
&#xD;
               -  Ongoing immune-modulator therapy for any concurrent illness&#xD;
&#xD;
               -  Chronic pain syndromes&#xD;
&#xD;
               -  Neurologic/neurodevelopmental disorders&#xD;
&#xD;
               -  Metabolic syndrome&#xD;
&#xD;
               -  Obesity (BMI &gt;30 kg/m2)&#xD;
&#xD;
               -  Malignant illnesses&#xD;
&#xD;
          -  Donor's diet will be monitored with a diet diary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajit Sood, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor and Head Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajit Sood, DM</last_name>
    <phone>+919779497094</phone>
    <email>ajitsood10@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dayanand Medical College and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Sood, DM</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 21, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>February 10, 2019</last_update_submitted>
  <last_update_submitted_qc>February 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dayanand Medical College and Hospital</investigator_affiliation>
    <investigator_full_name>Ajit Sood</investigator_full_name>
    <investigator_title>Professor and Head, Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>Induction of Remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

